ArticleMolecular therapy. Nucleic acids2019
An EV-Associated Gene Signature Correlates with Hypoxic Microenvironment and Predicts Recurrence in Lung Adenocarcinoma.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma.Aging · 2024Article
- Hypoxia Induces Tumor-Derived Exosome SNHG16 to Mediate Nasopharyngeal Carcinoma Progression through the miR-23b-5p/MCM6 Pathway.Applied biochemistry and biotechnology · 2024Article
- Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients.Scientific reports · 2023Article
- Hypoxia-Related Signature Is a Prognostic Biomarker of Pancreatic Cancer.Disease markers · 2022Article
- A prognostic signature model for unveiling tumor progression in lung adenocarcinoma.Frontiers in oncology · 2022Article
- Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response.Journal of translational medicine · 2021Article
- Small Extracellular Vesicles from Head and Neck Squamous Cell Carcinoma Cells Carry a Proteomic Signature for Tumor Hypoxia.Cancers · 2021Article
- Current Search through Liquid Biopsy of Effective Biomarkers for Early Cancer Diagnosis into the Rich Cargoes of Extracellular Vesicles.International journal of molecular sciences · 2021Review
- Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis.Bioscience reports · 2020Article
- Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells.International journal of molecular sciences · 2020Review
- Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy.Molecular therapy oncolytics · 2020Article
- Hypoxia differently modulates the release of mitochondrial and nuclear DNA.British journal of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) mediate intercellular communications in the tumor microenvironment and contribute to the aggressive phenomenon of cancers. Although EVs in body fluids are supposed to be ideal biomarkers for cancer diagnosis and prognosis, it remains difficult to distinguish the tumor-derived EVs from those released by other tissues. We hypothesized that analyzing the EV-related molecules in tumor tissues would help to estimate the prognostic value of tumor-specific EVs. Here, we investigate the expression of coding genes of proteins carried by small EVs (sEVs) in primary lung adenocarcinoma. Based on the protein-protein interaction network, we identified three network modules (3-PPI-Mod) as a signature that could predict recurrence. This signature was validated in three independent datasets and demonstrated better prognostic value than signature generated from gene expression alone. Meanwhile, the high-risk subgroup assigned by the signature could benefit from adjuvant chemotherapy, although it was not beneficial in unselected patients. Two out of three modules were enriched by proteins identified in sEVs from non-small-cell lung cancer cells. Furthermore, the two modules were remarkably correlated with intratumoral hypoxia score. These results suggest that the 3-PPI-Mod signature was enriched in tumor-derived sEVs and could serve as a prognostic and predictive biomarker for lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.